<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958074</url>
  </required_header>
  <id_info>
    <org_study_id>6914</org_study_id>
    <secondary_id>NCI-2009-01231</secondary_id>
    <nct_id>NCT00958074</nct_id>
  </id_info>
  <brief_title>Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well vorinostat works in treating
      patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer
      cells by blocking some of the enzymes needed for cell growth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the objective response rate to treatment with dose-adjusted Vorinostat
      schedule in subjects with cutaneous T-cell lymphoma (CTCL) who did not receive prior
      systematic therapy or have been treated with single agent targretin (bexarotene).

      SECONDARY OBJECTIVES:

      I. To determine the safety and tolerability of dose-adjusted Vorinostat schedule when
      administered to patients with primary cutaneous T-cell lymphoma who did not receive prior
      systematic therapy or have been treated with single agent targretin.

      II. To determine the time to objective response in subjects with CTCL treated with
      dose-adjusted schedule of Vorinostat as primary therapy.

      III To determine the duration of objective response in subjects with CTCL.

      IV. To determine the time to loss of objective response.

      V. To determine the objective response rate of extracutaneous manifestations of CTCL (lymph
      node enlargement, Sezary cells in peripheral blood).

      VI. To compare the efficacy, toxicity and tolerability of dose-adjusted schedule to currently
      recommended flat dose of Vorinostat in subjects with CTCL.

      OUTLINE: Patients are assigned to 1 of 2 treatment arms according to age (&lt; 65 vs &gt;= 65 years
      old).

      COHORT I (&gt;= 65 years old): Patients receive 200 mg vorinostat orally (PO) once daily (QD) on
      days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease
      progression or unacceptable toxicity.

      COHORT II (&lt; 65 years old): Patients receive 400 mg vorinostat PO QD on days 1-28. Treatment
      repeats every 28 days for 6 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for at least 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response</measure>
    <time_frame>After at least 14 days. With Confirmation after additional 28 days.</time_frame>
    <description>Defined as either no evidence of clinical disease or marked improvement (&gt;= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate of Extracutaneous Manifestations of CTCL (Lymph Node Enlargement, Sezary Cells in Peripheral Blood);</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>Assessed by changes in the sum of the products in the greatest diameters of enlarged lymph nodes by serial computed tomography (CT) or positron emission tomography (PET)/CT scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dose-adjusted Vorinostat</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>Toxicities will be graded in severity according to the guidelines outlined in the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sezary Cell Count Measured by Serial Flow Cytometry Measurements</measure>
    <time_frame>Baseline to 30 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Physicians Serial Assessment of Erythroderma Score</measure>
    <time_frame>Baseline to 30 days post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cutaneous T-cell Lymphoma Stage I</condition>
  <condition>Cutaneous T-cell Lymphoma Stage II</condition>
  <condition>Cutaneous T-cell Lymphoma Stage III</condition>
  <condition>Cutaneous T-cell Lymphoma Stage IV</condition>
  <arm_group>
    <arm_group_label>Cohort I (&gt;=65 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (&lt;65 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort I (&gt;=65 years old)</arm_group_label>
    <arm_group_label>Cohort II (&lt;65 years old)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>correlative study</description>
    <arm_group_label>Cohort I (&gt;=65 years old)</arm_group_label>
    <arm_group_label>Cohort II (&lt;65 years old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>correlative study</description>
    <arm_group_label>Cohort I (&gt;=65 years old)</arm_group_label>
    <arm_group_label>Cohort II (&lt;65 years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females

          -  Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary
             syndrome

          -  Documentation of diagnosis by histologic examination should be available

          -  Subjects with CTCL stages IB, IIA, IIB, III, or IVA who have not received any prior
             systemic therapies

          -  Anticipated life expectancy greater than 6 months

          -  Performance status 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG) criteria

          -  Written informed consent to participate in the study

          -  Absolute neutrophil count (ANC) &gt;= 1,000/mcL

          -  Platelets &gt;= 75,000/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Prothrombin time or international normalized ratio (INR) =&lt; 1.5 x upper limit of
             normal (ULN) unless receiving therapeutic anticoagulation

          -  Partial thromboplastin time (PTT) =&lt; 1.2 times the ULN unless the patient is receiving
             therapeutic anticoagulation

          -  Serum creatinine =&lt; 1.5 X ULN OR calculated creatinine clearance &gt;= 60 mL/min for
             patients with creatinine levels &gt; 1.5 X institutional ULN; creatinine clearance should
             be calculated per institutional standard

          -  Serum total bilirubin =&lt; 2 X ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic aminotransaminase [SGOT])
             and alanine aminotransferase (ALT) (serum glutamic pyruvic aminotransaminase [SGPT])
             =&lt; 3.0 X ULN

          -  Alkaline Phosphatase (liver fraction) =&lt; 3.0 X ULN

        Exclusion Criteria:

          -  Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB)

          -  Presence of lymphadenopathy is permitted

          -  ECOG performance status &gt; 2

          -  Concomitant use of any anti-cancer therapy or immune modifier

          -  Concomitant use of any investigational agent or device

          -  Concomitant therapy with any other anti-CTCL therapy, or radiation therapy (topical
             corticosteroids or low dose oral corticosteroids [=&lt; 10 mg/day prednisone or
             equivalent] will not be excluded, but if used, the dose and schedule must be stable
             during the two weeks immediately prior to study entry)

          -  Use of any previous systemic therapy (except single agent targretin), total skin
             electron beam (TSEB) therapy or extracorporeal photopheresis

          -  Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism

          -  Poorly controlled diabetes mellitus as evidenced by hemoglobin (Hgb)A1c &gt; 6.5 mg/dl

          -  Recent (in the past 6 months) medically significant cardiac event (i.e. myocardial
             infarction, cardiac surgery)

          -  Presence of congestive heart failure (New York Heart Association [NYHA] class IV) or
             angina (NYHA class IV) or presence of a medically significant arrhythmia

          -  Congenital long QT syndrome

          -  Corrected QT interval &gt; 480 msec on screening electrocardiogram (ECG)

          -  Presence of uncontrolled hypertension manifested by systolic blood pressure &gt;= 180
             mmHg and/or diastolic blood pressure &gt;= 100 mmHg

          -  Documented current active infection with human immunodeficiency virus (HIV), Hepatitis
             B, Hepatitis C, and/or cytomegalovirus (CMV)

          -  Presence of uncontrolled bacterial or viral infection (subject may be receiving
             chronic antimicrobial therapy)

          -  History of culture-documented bacteremia in the previous 2 weeks

          -  Concurrent therapy with any histone deacetylase (HDAC)-like compound; patients treated
             with valproic acid for epilepsy may enroll after a 30 day washout period

          -  Recent change (in the past 2 weeks) in the doses or regimens of medication used for
             any chronic non-oncologic conditions for reasons of worsening of chronic illness
             (change in doses of chronic medications associated with improvement in a chronic
             illness are not exclusion criteria)

          -  Presence of any acute or chronic non-oncologic disease which, in the opinion of the
             investigator, is medically uncontrolled

          -  History of a prior malignancy with the exception of cervical intraepithelial
             neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma
             with prostate specific antigen (PSA) &lt; 1.0; or who has undergone potentially curative
             therapy with no evidence of that disease for five years, and/or who is deemed at low
             risk for recurrence (&lt; 30% probability) by his/her treating physician

          -  Patient with a &quot;currently active&quot; second malignancy, other than nonmelanoma skin
             cancer and carcinoma in situ of the cervix, should not be enrolled

          -  Any significant medical or psychiatric condition that, in the opinion of the
             investigator, might prevent the subject from complying with all required study
             procedures

          -  Women of childbearing potential must have a pregnancy test within 28 days prior to
             registration, and must use an adequate method of contraception to avoid pregnancy
             throughout the study and for a period of at least 3 months after the study

          -  Females of childbearing potential and sexually active males, if indicated, must be
             willing and able to use two methods of contraception that are adequate to prevent or
             minimize risk of pregnancy for the duration of the study; one of which must be a
             barrier method

          -  Patient has symptomatic ascites or pleural effusion (a patient who is clinically
             stable following treatment for these conditions is eligible)

          -  Patient has had allogeneic transplant

          -  Patient has a history of a gastrointestinal surgery or other procedures that might, in
             the opinion of the investigator, interfere with the absorption or swallowing of the
             study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Shustov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>December 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2014</results_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort I (&gt;=65 Years Old)</title>
          <description>200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
        <group group_id="P2">
          <title>Cohort II (&lt;65 Years Old)</title>
          <description>400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I (&gt;=65 Years Old)</title>
          <description>200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
        <group group_id="B2">
          <title>Cohort II (&lt;65 Years Old)</title>
          <description>400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response</title>
        <description>Defined as either no evidence of clinical disease or marked improvement (&gt;= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.</description>
        <time_frame>After at least 14 days. With Confirmation after additional 28 days.</time_frame>
        <population>In cohort 1, only 3 of the 4 subjects consented were used for analysis. 1 patient in this cohort only completed 3 days of treatment before removing themselves from treatment and withdrawing consent. This patient was deemed inevaluable, as the timeframe for initial evaluation is 14 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (&gt;=65 Years Old)</title>
            <description>200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (&lt;65 Years Old)</title>
            <description>400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response</title>
          <description>Defined as either no evidence of clinical disease or marked improvement (&gt;= 50%) decrease in the modified Severity-Weighted Assessment Tool (mSWAT) skin assessment score compared to baseline.</description>
          <population>In cohort 1, only 3 of the 4 subjects consented were used for analysis. 1 patient in this cohort only completed 3 days of treatment before removing themselves from treatment and withdrawing consent. This patient was deemed inevaluable, as the timeframe for initial evaluation is 14 days.</population>
          <units>percentage of total</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate of Extracutaneous Manifestations of CTCL (Lymph Node Enlargement, Sezary Cells in Peripheral Blood);</title>
        <description>Assessed by changes in the sum of the products in the greatest diameters of enlarged lymph nodes by serial computed tomography (CT) or positron emission tomography (PET)/CT scans.</description>
        <time_frame>Up to 30 days post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dose-adjusted Vorinostat</title>
        <description>Toxicities will be graded in severity according to the guidelines outlined in the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.</description>
        <time_frame>Up to 30 days post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Sezary Cell Count Measured by Serial Flow Cytometry Measurements</title>
        <time_frame>Baseline to 30 days post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Physicians Serial Assessment of Erythroderma Score</title>
        <time_frame>Baseline to 30 days post-treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the time of signing consent until 30 days after the last dose of study drug treatment administered or until any treatment related AE or laboratory abnormality resolved or stabilized.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort I (&gt;=65 Years Old)</title>
          <description>200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
        <group group_id="E2">
          <title>Cohort II (&lt;65 Years Old)</title>
          <description>400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
vorinostat: Given PO
flow cytometry: correlative study
laboratory biomarker analysis: correlative study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>LOWER EXTREMITY EDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HEARING LOSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TASTE CHANGE (Dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ABRASION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>FOOT PAIN (FOOT TENDERNESS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HAIR LOSS (ALOPECIA)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SCALP PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>TREMORS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS (ANOREXIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ELEVATED CREATININE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ELEVATED GLUCOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LEG CRAMPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>MUSCOLOSKELETAL PAIN (BACK)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ITCHING/ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN CRACKING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN SHEDDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SKIN THICKENING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Andrei Shustov</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-6744</phone>
      <email>ashustov@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

